
Glenmark Pharmaceuticals Ltd. has received final approval from the U.S. FDA for Fluphenazine Hydrochloride Tablets USP in various strengths, the generic version of Prolixin® Tablets by Apothecon Inc. These tablets (1 mg, 2.5 mg, 5 mg, and 10 mg) will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. The market for Prolixin® Tablets achieved approximately $18.1 million in annual sales, according to IQVIATM data ending September 2023. Glenmark currently has 189 products authorized for U.S. distribution and 50 ANDAs pending FDA approval, with ongoing efforts to expand its pipeline and portfolio through internal and external collaborations.
Like
Save
Share